Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test
The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo’s Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder
Preclinical Data Demonstrates MEB–1170 Lacks Adverse Effects of Opioids Including Respiratory Depression and Opioid Abuse Potential
Dr. Sean Lyden Agrees to Assume the Role of Chief Medical Consultant and Join the VESTECK Scientific Advisory Board
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
BioAdvance Breaks Life Sciences Investing Record Year in 2022
Nearly $5 million invested in eight new promising Mid-Atlantic life sciences companies
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
– IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing
– EPN1 appears to play an important role in cancer formation and progression, and IMM20059 may have the ability to improve response to immunotherapy
– Combinatorial effect (> 50% reduction in tumor volume) was demonstrated with IMM20059 and anti-PD-L1 treatment atezolizumab